Vogt Frederick G 4

What Happened
Frederick G. Vogt, Interim CEO, General Counsel and a director of Iovance Biotherapeutics (IOVA), received a grant of 235,000 restricted stock units (RSUs) on March 9, 2026. The award was reported as a derivative acquisition at $0.00 (no immediate cash paid or proceeds received). RSUs represent a contingent right to receive one share of common stock upon vesting.

Key Details

• Transaction date and type: March 9, 2026 — Award/Grant (code A), 235,000 RSUs, reported at $0.00.
• Vesting: RSUs vest over three years — one-third on the one-year anniversary, then the remaining two-thirds in eight equal quarterly installments over the next two years (vesting installments begin the quarter after the first anniversary). (Footnotes F1, F2)
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing date: Form 4 filed March 11, 2026 (two days after the grant); appears to have been filed within the standard reporting window.
• Nature of award: Derivative grant (RSUs) — no immediate market transaction or sale; value realized only as RSUs vest and shares are issued.

Context
RSU grants are commonly used for executive compensation and retention; they do not represent a market purchase or sale and carry no immediate cash value until vested and settled into shares. This filing documents the grant itself and the contractual vesting schedule; it does not indicate any immediate buying or selling of company stock.